Leyden Labs Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Leyden Labs's estimated annual revenue is currently $14.7M per year.(i)
  • Leyden Labs's estimated revenue per employee is $155,000

Employee Data

  • Leyden Labs has 95 Employees.(i)
  • Leyden Labs grew their employee count by 34% last year.

Leyden Labs's People

NameTitleEmail/Phone
1
Head DiscoveryReveal Email/Phone
2
Director CMCReveal Email/Phone
3
Senior Director / Head Clinical DevelopmentReveal Email/Phone
4
Senior Clinical Trial ManagerReveal Email/Phone
5
Senior Clinical Trial ManagerReveal Email/Phone
6
Procurement ManagerReveal Email/Phone
7
Clinical Trial ManagerReveal Email/Phone
8
Principal StatisticianReveal Email/Phone
9
Laboratory AssistantReveal Email/Phone
10
Senior Scientist - ImmunologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Leyden Labs?

keywords:N/A

N/A

Total Funding

95

Number of Employees

$14.7M

Revenue (est)

34%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Leyden Labs News

2022-04-17 - Who's who of biopharma execs backs tiny Dutch startup's bid ...

... of development, Onno van de Stolpe, former CEO of Galapagos, Daniel de Boer, CEO of ProQR, and Dinko Valerio, co-founder of Leyden Labs.

2022-04-17 - 2022 Henri Termeer Transatlantic Connections Award Honorees Announced by Termeer Foundation as Part of Program Supporting Emerging Life Science Leaders in the Netherlands and Massachusetts

Kasper Roet, of QurAlis Corporation and Koenraad Wiedhaup, of Leyden Labs presented with annual award at Innovation for Health conference in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20M9530%N/A
#2
$27.6M953%N/A
#3
$31.2M958%N/A
#4
N/A95-2%N/A
#5
$14.3M958%N/A